New Research Highlights Advances in Pediatric Endocrinology and Oncology Collaboration

Recent collaborative efforts between the University of Florida’s Department of Pediatrics and the Princess Máxima Center for Pediatric Oncology in the Netherlands have advanced understanding of hormonal interactions in childhood cancer patients, according to a study published in JAMA Pediatrics. The research, led by Dr. Emily Zhang of the University of Florida and Dr. Lars van der Meer of the Princess Máxima Center, focuses on how endocrine system changes during cancer treatment affect long-term metabolic health in survivors.

Key Findings from the Study

The study analyzed data from over 1,200 pediatric oncology patients treated between 2015 and 2022. Researchers found that 38% of participants developed at least one endocrine-related complication, such as growth hormone deficiency or thyroid dysfunction, within five years of completing cancer therapy. These findings underscore the need for integrated endocrinology care during and after cancer treatment, the authors note.

“Children undergoing cancer treatment face unique challenges where their developing endocrine systems are often impacted by chemotherapy, radiation, or surgery,” said Dr. Zhang. “Our work highlights the importance of monitoring and managing these effects to improve long-term quality of life.”

Collaborative Framework Between U.S. and Dutch Institutions

The partnership between the University of Florida and the Princess Máxima Center, established in 2020, combines the U.S. institution’s expertise in pediatric endocrinology with the Dutch center’s leadership in pediatric oncology. The collaboration includes shared clinical protocols, joint research initiatives, and training programs for medical professionals.

“This cross-border collaboration allows us to pool resources and data that would be difficult to achieve in isolation,” said Dr. van der Meer. “By focusing on both cancer treatment and its endocrine consequences, we’re addressing the full spectrum of care for young patients.”

Implications for Clinical Practice

The study recommends that all pediatric oncology patients undergo regular endocrine screening, particularly those receiving treatments known to disrupt hormone production. Guidelines also emphasize the role of multidisciplinary teams in managing complications, including endocrinologists, oncologists, and nutritionists.

Dr. Maria Lopez, a pediatric endocrinologist at the University of Florida not involved in the study, praised the research for its practical focus. “These findings provide actionable steps for clinicians to better support their patients,” she said. “It’s a critical step toward more holistic care for childhood cancer survivors.”

Future Directions in Pediatric Endocrinology Research

Building on this work, the research team plans to explore the genetic factors that may predispose children to endocrine complications. They also aim to develop targeted interventions, such as hormone replacement therapies tailored to specific cancer treatments.

“We’re moving toward a model where endocrine health is considered a core component of cancer care, not an afterthought,” said Dr. Zhang. “This study is just the beginning of a broader effort to redefine standards of care.”

Why This Matters for Patients and Families

For families of childhood cancer survivors, the study offers hope for better long-term outcomes. Endocrine complications can lead to issues like delayed growth, obesity, or early onset of chronic diseases, but early detection and management can mitigate these risks. The research also highlights the importance of follow-up care, which many families may not fully understand.

“This work gives us more tools to advocate for our children’s health beyond their cancer diagnosis,” said Sarah Mitchell, a parent and founder of the Childhood Cancer Survivor Network. “Knowing that specialists are working to address these challenges gives us confidence in their care.”

As the field of pediatric endocrinology continues to evolve, the collaboration between U.S. and Dutch institutions serves as a model for international research efforts. With ongoing studies and clinical advancements, the focus remains on improving both survival rates and the quality of life for children affected by cancer.